



Author Index
Volume 52
July—December 1995

- Acosta, M., 17
Aire, T.A., 255, 261
Aitken, R.J., 241
Allen-Davis, J., 45
Amatya, R., 17
Anderson, F., 313
Anderson, F.D., 167
Anderson, N.G., 287
Anderson, R.A., 115
Andersson, K., 175
Ankum, W.M., 337
Arcner, D.F., 167
Asthana, O.P., 297, 301
Athayde, C., 111
Aydinlik, S., 343

Bajaj, J.S., 121, 381
Bancroft, J., 363
Barbosa, I., 111
Bateman, L., 159
Bennink, H.C., 357
Benzi, G., 93
Biro, F.M., 283
Bossuyt, P.M.M., 337
Braunschweig, T., 343
Broome, M., 13
Buekens, P., 23
Bundren, J.C., 277
Burnhill, M.S., 137

Castracane, V.D., 371
Chatterton, Jr, R.T., 195
Chen, C., 99
Chen, J., 63
Chen, Y., 129
Cheng, J., 63
Ciuffetti, G., 151
Clarkson, J.S., 241
Clayton, J., 13
Coata, G., 151
Cosmi, E.V., 151
Coutinho, E., 111
Creinin, M.D., 41
Crook, D., 143
Cui, Y., 63

Deniaud, F., 223
Devenport, M., 143
Di Renzo, G.C., 151
Diczfalusy, E., 1
Dieben, T., 357
Ditmore, J.R., 159

Du, M., 99
Dugoff, L., 45
Düsterberg, B., 229

Ekwempu, C., 17
Elger, W., 187
Endrikat, J., 229
Exalto, N., 357

Fahnrich, M., 187
Farley, T.M.M., 363
Farr, G., 17
Ferraroni, M., 93
Fink, W., 215
Fotherby, K., 13
Frank, M.L., 159
Friel, P., 223

Gao, Y., 99
Garza-Chapa, R., 377
Gaspard, U.J., 237
Gebbie, A.E., 221
Gerofi, J., 223
Gillan, L., 317
Gimpel, T., 371
Glasier, A., 221
Godsland, I.F., 143
Goldzieher, J.W., 327, 371
González-Garza, M.T., 377
González-Quiroga, G., 377
Graham, C.A., 363
Grimes, D.A., 137
Grubb, G.S., 287
Gu, S., 99
Gu, Z., 57, 63
Gudmundson, J., 35
Gupta, R.C., 297, 301
Gurr, S., 343

Hasan, S.H., 187
He, X., 99
Hendrick, J.C., 237
Hillard, P.J.A., 137, 283
Hodgen, G.D., 313
Hu, J., 63
Huimin, F., 349
Hurst, B.S., 45

Ilegbodu, A.E., 159
Islam, M.M., 181

Jaques, M.-A., 229
Jernstrom, H., 51

Jeyendran, R.S., 195
Jonasson, K., 175
Jones, A.R., 317
Jones, III, O.W., 45

Kaufmann, J., 343
Kazer, R.R., 195
Kim, S., 313
Kinger, S., 121, 381
Kisnisci, H., 17
Klinger, G., 343
Knutsson, M., 51
Kollar, L.M., 283
Kumar, P.K.S., 121, 381

La Vecchia, C., 93
Ladipo, O., 111
Lal, J., 297, 301
Lian, S., 63
Lidegaard, Ø., 85
Lindstedt, G., 175
Liu, X., 63
Liu, Y., 99
Lombardini, R., 151
Lozano-Garza, G., 377
Luo, H., 57, 63
Luukkainen, T., 269

Maglaya, C., 363
Mahmud, M., 181
Mauck, C.K., 167
Mayerhofer, M., 229
McDougall, C., 215
McKinney, S., 277
Meng, F., 99
Milimlow, D., 317
Milsom, I., 175
Mol, B.W.J., 337
Moore, D., 287
Moore, L.L., 215
Moutos, D., 105
Müller, U., 229

Naessen, T., 35
Nervo, P., 237
Nityanand, S., 297, 301
Nwoha, P.U., 249, 255, 261

Olsson, H., 51
Olsson, S.E., 35, 111

Pal, P.C., 121, 381

Paliwal, J.K., 301
Parazzini, F., 93
Park, M., 41
Pelissier, C., 229
Peters, A.J., 195
Poindexter, III, A.N., 159
Premakumara, G.A.S., 203
Pruthi, J.S., 381

Qi, L., 99

Rajalakshmi, M., 121, 381
Ramos, R., 363
Ratnasooryia, W.D., 203, 241
Rauh, J.L., 283
Ray, R.M., 307
Rosenberg, M.J., 137
Rosenthal, S.L., 283
Rossi, G., 93
Rybo, G., 175

Said-Fernández, S., 377
Schelhorn, P., 343
Schlaff, W.D., 45
Sharma, D.N., 121
Shirley, B., 277
Shuhua, Q., 349
Siegert, C., 343
Singh, M.M., 187

Sivin, I., 99
Smith, S., 105
Snipes, W., 313
Sweeting, V., 221

Teng, C.S., 129, 389
The WHO Collaborative Study of
Neoplasia and Steroid Con-
traceptives, 307
Thomas, D.B., 307
Tillekeratne, L.M.V., 203
Toivonen, J., 269
Tozzi, L., 93

Ulmsten, U., 111
UNDP, UNFPA, and WHO Spe-
cial Programme of Research,
Development and Research
Training in Human Repro-
duction, World Bank: IUD
Research Group, 77

Valuck, R., 215
van den Brûle, F.A., 237
van der Does, J., 357
Van der Veen, F., 337
Ventura, F., 151
Viniegra-Sibal, A., 167

Wallace, E.M., 115
Wang, D., 99
Wang, J., 63
Wang, P., 99
Waugh, M.S., 137
Wendler, J., 343
Wentz, A.C., 195
White, D.R., 241
Wollast, E., 23
Wu, F.C.W., 115
Wu, S., 57, 63, 99
Wynn, V., 143

Xiong, X., 23
Xu, L., 63
Xu, R., 63

Yang, N.Y., 129
Ying, L., 99

Zacur, H., 105
Zamah, N.M., 327
Zenger, E., 349
Zhang, G., 57
Zhang, L., 99
Zhu, P., 57, 63
Zhu, X., 57



Subject Index
Volume 52
July–December 1995

- Acceptability,
condom use, 223
methotrexate + misoprostol, 41
Norplant implants, 159
Adolescent contraceptive use, 181
Adolescents, Norplant implants use, 283
Anordiol, effect on uterus and vagina (rat), 195
Antide, gonadotropin-releasing hormone agonist, 381
Antisteroid antibodies, OC users, 237
- Barrier contraceptive, Lea's Shield, 167
Barrier contraceptive use, risk of ectopic pregnancy, 93
Blood chemistry, effect of gossypol (male rat), 249
Blood pressure, combined OCs, 143
Blood viscosity, effect of triphasic ethynodiol + gestodene, 151
Bone density, effects of progestogen-only contraceptives, 15
Breast milk, centchroman levels, 301
3-Bromopyruvate, effect on spermatozoa (boar), 317
Buccal administration, testosterone, 313
- Centchroman, pharmacokinetics, 297
Centchroman concentration, serum and breast milk, 301
Cerebral thromboembolism risk, OC use, 85
Cervical carcinomas, depo-medroxyprogesterone acetate use, 307
Chloroquine,
effect on cholesterol and triglycerides levels (male rat), 261
effect on serum electrolytes (male rat), 255
Cholesterol level, effect of gossypol + chloroquine (male rat), 261
Clinical performance,
Lippes Loop, 17
TCu 380A, 17
Clinical trial,
ethynodiol + desogestrel, 229
ethynodiol + gestodene, 229
FlexiGard, 77
Norplant implants, 45, 99, 283, 287, 349
TCu 380A, 77
Clomiphene citrate, effect on uterus and vagina (rat), 195
Coagulation parameters, triphasic ethynodiol + gestodene, 151
Combined OCs,
effect on blood pressure, 143
metabolic effects, 143

- Compliance, oral contraceptive use, 137
Condom, design and user acceptability, 223
Contraceptive efficacy, hormone replacement therapy, 221
Contraceptive mechanism, Sri Lankan marine red algae (rat), 203
Contraceptive method use, risk of ectopic pregnancy, 93, 337
- Early removal, Norplant implants, 159
Ectopic pregnancy,
contraceptive methods, 337
effect of IUD use, 23
effect of past contraceptive method use, 93
Emergency contraceptive, consensus statement, 211
Endometrium, effect of levonorgestrel-releasing IUD, 57, 63
Erythrocytic enzymes, effect of gossypol (male hamster), 377
Ethynodiol + cyproterone acetate, 343
Ethynodiol + desogestrel, 229, 357
Ethynodiol + gestodene, 151, 229
Ethynodiol + levonorgestrel, 13, 343, 357, 363
Ethynodiol + norethindrone, 105
- FlexiGard, frameless IUD, 77
FSH (follicle stimulating hormone)
FSH levels, effect of oral contraceptive use, 51
- Gossypol,
effect on blood chemistry (male rat), 249
effect on cholesterol and triglycerides levels (male rat), 261
effect on erythrocytic enzymes (male hamster), 377
effect on serum electrolytes (male rat), 255
effect on spermatocytes (rat), 389
effect on spermatogenesis (rat), 129
Gyne-T 380S, 175
- Hormonal parameters, effect of testosterone buciclate (male monkey), 121
Hormonal replacement therapy, 371
Hormone levels, effect of ethynodiol + norethindrone, 105
Hormone replacement therapy, 221
- Implant contraceptive,
levonorgestrel, 35, 45, 99, 159, 215, 283, 287, 349
norgestimate, 111

- Injectable contraceptive, depot-medroxyprogesterone acetate, 35, 215, 307
- Intrauterine device (IUD),
 FlexiGard, 77
 Gyne-T 380S, 175
 Lippes Loop, 17
 releasing levonorgestrel, 57, 63, 269
 TCu 380A, 17, 77
- Iron status, Gyne-T 380S, 175
- IUD (see intrauterine device)
- IUD use, risk of ectopic pregnancy, 23, 93
- Labeling guidance text, progestin-only OCs, 71
- Lea's Shield, vaginal barrier contraceptive, 167
- Levonorgestrel,
 effect on bone density, 35
 effect on ovaries, 13
 effect on well-being and sexuality, 363
 post-coital contraceptive (mouse), 277
- Levonorgestrel-releasing IUD, effect on endometrium, 57, 63, 269
- LH (luteinizing hormone)
 LH levels, effect of oral contraceptive use, 51
- Lipid metabolism, triphasic ethinyl estradiol + gestodene, 151
- Lipoproteins, effect of testosterone enanthate, 115
- Lippes Loop, 17
- Male contraceptive, intramuscular testosterone enanthate, 115
- Marine red algae, contraceptive mechanism (rat), 203
- Medical abortion, methotrexate + misoprostol, 41
- Medroxyprogesterone acetate,
 effect on bone density, 35
 effect on weight gain, 215
 risk of cervical carcinomas, 307
- Menopause, switch from OCs to hormonal replacement therapy, 371
- Menstrual blood loss, Gyne-T 380S, 175
- Metabolic effects,
 combined OCs, 143
 nomegestrol acetate, 111
- Methotrexate + misoprostol, medical abortion, 41
- Minipills, labeling guidance text, 71
- Morning-after contraception, 211
- Nomegestrol acetate subdermal implant, 111
- Nonoxynol-9, effect on sperm motility, 241
- Norethisterone, 13
- Norplant® subdermal implants, 35, 45, 99, 159, 215, 283, 287, 349
- OC use,
 cerebral thromboembolism risk, 85
 compliance, 137
 effect on FSH and LH levels, 51
 risk of ectopic pregnancy, 93
 switch to hormonal replacement therapy, 371
- OC users, vascular events, 237
- Onapristone, effect on pregnancy (guinea pig), 187
- Oral contraceptive (OC),
 centchroman, 297, 301
 combined formulations, 143
 ethinylestradiol + cyproterone acetate, 343
 ethinylestradiol + desogestrel, 229, 357
 ethinylestradiol + gestodene, 229
 ethinylestradiol + levonorgestrel, 343, 357, 363
 ethinylestradiol + norethindrone, 105
 levonorgestrel, 13, 363
 minipills, 71
 norethisterone, 13
 progestin-only, 71
 side effects, 327
 triphasic ethinylestradiol + gestodene, 151
 triphasic ethynodiol + levonorgestrel, 13
- Ovarian activity,
 effect of triphasic ethinylestradiol + levonorgestrel, 357
 effect of triphasic ethinylestradiol + desogestrel, 357
- Ovarian cyst formation, effect of oral contraceptives, 13
- Ovulation, effect of hormone replacement therapy, 221
- Pharmacokinetics,
 centchroman, 297
 testosterone, 313
- Phoniatric examinations, use of OCs, 343
- Post-coital contraception, 211
- Post-coital contraceptive, levonorgestrel pellets (mouse), 277
- Pregnancy, effect of Onapristone (guinea pig), 187
- Prempak-C, hormone replacement therapy, 221
- Progestin-only OCs, labeling guidance text, 71
- Progesterone-only OCs, effect on bone density, 35
- Propranolol, effect on sperm motility, 241
- Psychological effects, use of OCs, 363
- Removal, Norplant implants, 159
- Reproductive health, commentary, 1
- Reproductive parameters, effect of testosterone buciclate (male monkey), 121
- Reproductive tract infections and HIV/AIDS, 1
- Sexuality, effect of OCs, 363
- Side effects, oral contraceptives, 327
- Sperm motility, effect of nonoxynol-9 + propranolol, 241
- Spermatocytes, effect of gossypol (rat), 389
- Spermatogenesis,
 effect of Antide + testosterone buciclate (monkey), 381
 effect of gossypol (rat), 129
- Spermatozoa, effect of 3-bromopyruvate (boar), 317
- Sri Lankan marine red algae, contraceptive mechanism (rat), 203

Switch from OCs to hormonal replacement therapy, 371

TCu 380A, 17, 77

Testosterone,

 pharmacokinetics, 313

 transbuccal delivery system, 313

Testosterone buciclate, effect on reproductive and
 hormonal parameters (male monkey), 121

Testosterone buciclate + Antide (male monkey), 381

Testosterone enanthate, effect on lipoproteins, 115

Triglycerides level, effect of gossypol + chloroquine
 (male rat), 261

Uniplant subdermal implant, 111

Uterus, effect of anordiol (rat), 195

Vagina, effect of anordiol (rat), 195

Vascular events, OC users, 237

Voice function, effect of OCs, 343

Weight gain, users of contraceptives, 215